FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the H.C. Wainwright 27thAnnual Global Investment Conference taking place September 8-10 at the Lotte New York Palace Hotel in New York City.

FibroBiologics will deliver a company presentation at 12:00 p.m. ET on September 10 and be available for one-on-one investor meetings throughout the event.

For more information, please visit FibroBiologics’websiteor email FibroBiologics atinfo@fibrobiologics.com.

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visitwww.FibroBiologics.com.